Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
Beteiligte Einrichtungen
Abstract
We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D-mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment.
Bibliografische Daten
| Originalsprache | Englisch |
|---|---|
| Aufsatznummer | 29 |
| ISSN | 0732-183X |
| Status | Veröffentlicht - 2012 |
| pubmed | 22734028 |
|---|
